Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Myriad Genetics (MYGN) Return on Sales: 2010-2025

Historic Return on Sales for Myriad Genetics (MYGN) over the last 16 years, with Sep 2025 value amounting to -0.49%.

  • Myriad Genetics' Return on Sales fell 34.00% to -0.49% in Q3 2025 from the same period last year, while for Sep 2025 it was -0.49%, marking a year-over-year decrease of 34.00%. This contributed to the annual value of -0.15% for FY2024, which is 20.00% up from last year.
  • Per Myriad Genetics' latest filing, its Return on Sales stood at -0.49% for Q3 2025, which was down 2.27% from -0.47% recorded in Q2 2025.
  • In the past 5 years, Myriad Genetics' Return on Sales registered a high of -0.01% during Q1 2022, and its lowest value of -0.49% during Q3 2025.
  • Moreover, its 3-year median value for Return on Sales was -0.30% (2024), whereas its average is -0.29%.
  • Per our database at Business Quant, Myriad Genetics' Return on Sales climbed by 30bps in 2021 and then slumped by 34bps in 2025.
  • Quarterly analysis of 5 years shows Myriad Genetics' Return on Sales stood at -0.04% in 2021, then fell by 13bps to -0.17% in 2022, then dropped by 18bps to -0.35% in 2023, then increased by 20bps to -0.15% in 2024, then plummeted by 34bps to -0.49% in 2025.
  • Its last three reported values are -0.49% in Q3 2025, -0.47% for Q2 2025, and -0.12% during Q1 2025.